Login
$CATX
$0.94 +$0.01 (1.32%) After hours

$CATX 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

Updated interim data from the Phase 1/2a bamzireotide navoxetan (VMT-α-NET) presentations continue to support an emerging therapeutic window and potential to achieve a best-in-class profile in NETs

06 Nov 2026 8-K: Other Events

Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026

06 Nov 2026 8-K: Other Events

Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs

23 Oct 2026 8-K: Other Events

Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs

08 Oct 2026 8-K: Other Events

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors

01 Oct 2026 8-K: Other Events

Next-Generation Radiopharmaceuticals Redefining Targeted Oncology

14 Sep 2026 8-K: Other Events

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors

08 Sep 2026 8-K: Other Events

Next-Generation Radiopharmaceuticals Redefining Targeted Oncology

10 Aug 2026 8-K: Results of Operations and Financial Condition; Other Events

Advancing VMT-α-NET toward a Phase 3 study in neuroendocrine tumors, subject to regulatory alignment: regulatory engagement ongoing; clinical site activation targeted around year-end 2026 subject to regulatory feedback; sufficient isotop...

03 Aug 2026 8-K: Other Events

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

01 Jul 2026 8-K: Other Events

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

01 Jun 2026 8-K: Other Events

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

27 May 2026 8-K: Submission of Matters to a Vote of Security Holders

On May 27, 2026, Perspective Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 114,017,755 shares of common stock outstanding and entitled to vote at the Annual Meeting, 97,882...

22 May 2026 8-K: Other Events

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

11 May 2026 8-K: Results of Operations and Financial Condition; Other Events

Differentiated ²¹²Pb radiopharmaceutical platform designed to optimize tumor killing, safety, patient convenience and supply scalability

04 May 2026 8-K: Results of Operations and Financial Condition; Other Events

Direct-to-Hospital Delivery through Integrated Isotope Production

20 Apr 2026 8-K: Other Events

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

01 Apr 2026 8-K: Other Events

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

16 Mar 2026 8-K: Results of Operations and Financial Condition; Other Events

Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026

03 Feb 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Pre-Funded Warrants to Purchase 6,598,046 Shares of Common Stock

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support